Equity Research Medical Care Facilities

Should You Buy AirSculpt Technologies, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 3/13 models active

According to the CirclFi Deep Alpha Valuation Engine, AirSculpt Technologies, Inc. (AIRS) carries a solid Quality of Company rating of 6.1/10. Trading at $2.61, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 3 CirclFi valuation models project upside for AirSculpt Technologies, Inc. (AIRS) at $2.61 — the model consensus leans bearish, with a Quality Score of 6.1/10 and Value-Trap risk of 28/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 3 models suggest overvaluation — majority bearish
  • Quality Score: 6.1/10 — Moderate — mixed signals
  • Value Trap Risk: 28/100 — Low — manageable risk
  • Fair Value Range: $0.21 – $2.19 (965% spread)

Bullish Models

0 / 3

Bearish Models

3 / 3

Quality Score

6.1 /10

Moderate — mixed signals

Value Trap Risk

28 /100
Low

Low — manageable risk

Model Consensus

3 /13
Active Models

Avg. confidence: 49%

What Is the Investment Case for AirSculpt Technologies, Inc. (AIRS) in 2026?

What Is the Bull Case vs the Bear Case for AirSculpt Technologies, Inc. (AIRS)?

Bull case versus bear case for AirSculpt Technologies, Inc. (AIRS) at $2.61, derived from 3 active CirclFi valuation models on 2026-08-27.
Bull case Bear case — $0.21 target (-92.1%)
No active model projects meaningful upside for AIRS at $2.61. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $0.21 (-92.1%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +76.0% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does AIRS Compare to Its Medical Care Facilities Peers?

RHEP Regional Health Prop
6.2
MCTA Charming Medical Lim
6.1
SGRY Surgery Partners, In
6.4
CCM Concord Medical Serv
6.1
SRTA Strata Critical Medi
6.5
SYRA Syra Health Corp.
5.9
BICX BioCorRx Inc.
4.9
ENSG The Ensign Group, In
8.5

Valuation data pages: RHEP · MCTA · SGRY · CCM · SRTA · SYRA · BICX · ENSG · CON · ADUS · NHC

See full Medical Care Facilities rankings →

Which Other Stocks Score Like AIRS on Quality?

Closest companies to AIRS’s Quality of Company score of 6.1/10, across all industries.

Why Do CirclFi’s 3 Models Disagree on AIRS?

Spread

965%

Fair Value Range

$0.21 – $2.19

A 965% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$2.19 (-16.1%)

Most Bearish

RCMH-DCF

$0.21 (-92.1%)

What Are the Biggest Risks of Buying AIRS Stock?

Model Disagreement

965% spread signals high variance in projections.

Bearish Consensus

3/3 models suggest overvaluation.

Macro/Sector Risk

Medical Care Facilities headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View AIRS Data Page →

So Is AirSculpt Technologies, Inc. (AIRS) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on AirSculpt Technologies, Inc. at $2.61. 3/3 models flag overvaluation, median fair value sits at $0.23 (-91.1%), and the risk-reward profile appears unfavorable. Quality at 6.1/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. AirSculpt Technologies, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About AIRS Stock?

Should I buy AIRS stock right now?

Based on CirclFi's multi-model analysis, 0 of 3 models see upside for AIRS at $2.61. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in AirSculpt Technologies, Inc.?

Key risks include: limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (965% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.

How does AIRS compare to its competitors?

Among Medical Care Facilities peers, AIRS holds a Quality Score of 6.1/10. Comparable companies include RHEP (QOC 6.2), MCTA (QOC 6.1), SGRY (QOC 6.4). The relative ranking helps investors identify whether AIRS offers better fundamental quality than alternatives in the same sector.

Is AIRS a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AIRS's Quality Score of 6.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy AIRS at?

CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $0.21 to $2.19. At $2.61, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for AIRS.

View AIRS Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →